DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2

Summary

This open-label Phase I study aims at assessing primarily the safety of the NKR-2 treatment administered after a non-myeloablative preconditioning regimen in r/r AML/MDS patients. This Phase I study will contain two different sequential segments. The first segment will determine the recommended investigational treatment option (schedule of preconditioning and NKR-2 dose) and the second segment will expand to a larger number of r/r AML/MDS patients.

Timeline

Start

2018-09-18

Primary completion

2021-02-01

Completion

2021-02-01

Drugs

Indications